892414-46-9

Usage

Uses

Used in Pharmaceutical Research:
1H-Pyrrolo[2,3-b]pyridin-3-ol, 2,3-dihydro-3-(trifluoroMethyl)is used as a key intermediate in the synthesis of various pharmaceutical compounds for the treatment of different diseases. Its unique structure allows for the development of new drugs with novel mechanisms of action and improved therapeutic profiles.
Used in Agrochemical Research:
In the agrochemical industry, 1H-Pyrrolo[2,3-b]pyridin-3-ol, 2,3-dihydro-3-(trifluoroMethyl)is utilized as a building block for the creation of new crop protection products. Its potential biological activity and chemical properties make it a promising candidate for the development of innovative pesticides and herbicides that can effectively protect crops from pests and diseases while minimizing environmental impact.

Upstream product

• 372-48-5 2-fluoropyridine 
• 932406-33-2 2,2,2-trifluoro-1-(2-fluoropyridin-3-yl)ethane-1,1-diol 
• 892414-45-8 1,1,1-trifluoro-2-(2-fluoropyridin-3-yl)-3-nitropropan-2-ol 

Downstream Products

• 892414-47-0 3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 892414-50-5 6-chloro-4-nitro-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 892414-51-6 6-chloro-4-nitro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine 
• 892414-55-0 4-[(6-chloro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]-pyridin-4-yl)oxy]-3,5-difluoroaniline 
• 932406-43-4 benzyl (6-chloro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)(2-fluoro-4-nitrophenyl)acetate 
• 1342811-50-0 C₁₅H₈BrF₃N₂O 
• 1150618-36-2 5-bromo-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 1620574-99-3 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

Improved synthesis of the selective rho-kinase inhibitor 6-chloro-n4-{3,5-difluoro-4-[(3-methyl-1h-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl} pyrimidin-2,4-diamine

A highly potent and selective Rho-kinase inhibitor containing a 7-azaindole moiety has been developed at Bayer Schering Pharma. Herein we disclose details of a significantly improved synthesis of the compound in 8.2% overall yield. Key aspects include cost and safety considerations and the uncommon use of a trifluoromethyl group with controllable reactivity as a masked methyl group.

Synthesis and derivatization of 3-perfluoroalkyl-substituted 7-azaindoles

An expedient large-scale synthesis of 3-perfluoroalkyl-7-azaindoles starting from 2-fluoropyridine is presented. The activation as 6-chloro-4-nitro derivative allows the further derivatization by nucleophilic aromatic substitution in the 4-position. Georg